Voxelotor 300mg; tabs for oral susp; grape flavor. Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS and exhibits preferential partitioning to red blood cells. By ...

Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.4-6 The sickling process causes hemolytic anemia (low hemoglobin due ...

In the U.S., the hemoglobin S (HbS) polymerization inhibitor was granted accelerated approval for SCD in 2019 based on data from the phase III HOPE trial, which showed a better hemoglobin response ...

Voxelotor (GBT440, Global Blood Therapeutics) — a novel hemoglobin S polymerization inhibitor administered orally once daily — previously received fast track, orphan ...

OXBRYTA works by increasing hemoglobin’s affinity for oxygen. OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells leading to ...

The company's flagship product, Voxelotor, is an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which is hypothesized to inhibit hemoglobin polymerization in patients ...

Fetal hemoglobin is resistant to polymerization and, when present in sufficient quantity, is thought to disrupt the polymerization of sickle cell hemoglobin. Using these new models, ...

The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD.

Hemoglobin beta gene (β-HBB) mutations characterize the congenital disease. Heme oxygenase 1, a member of the heat shock protein (HSP32) family, causes ferroptosis and sickling of red blood cells.